Thursday, July 31, 2008

Press Release: 3QMatrix to Commercialize Wound Healing Technology from Univ. of Colorado

(LINK)

BOULDER, Colo. (July 31, 2008) - The University of Colorado’s Technology Transfer Office (CU TTO) has executed an exclusive option agreement with 3QMatrix, Inc. for degradable thiol-ene hydrogel technology developed in the laboratories of Christopher Bowman, Associate Dean for Research, and Kristi Anseth, Distinguished Professor and HHMI Investigator, both in the Department of Chemical & Biological Engineering at the University of Colorado at Boulder. Founded in 2008 by local entrepreneurs Johan Baeck, Praful Shah and Tim Prodanovich, Boulder-based 3QMatrix is focused on the development and commercialization of novel wound healing and drug delivery products based on the proprietary thiol-ene hydrogel product platform.

The company’s first product will be a bi-layer dressing for treatment of skin graft donor sites in burn patients. These donor sites are prone to infection and extremely painful, especially since their dressings must be changed frequently. “The thiolene-based bi-layer dressing, since it degrades in a controlled fashion at the wound site, has the potential to eliminate the frightful pain associated with donor site dressing changes, and hence be of tremendous importance to thousands of burn patients,” notes Dr. Gordon Lindberg, Director of the Burn Center at University of Colorado Hospital Burn Center and member of 3QMatrix’s Scientific Advisory Board.

“3QMatrix shows the value of opening CU's patent portfolio to entrepreneurs in the Boulder community who know how to drive a new business forward,” adds Kate Tallman, Director of Technology Transfer for CU-Boulder. 3QMatrix was developed and launched through a partnership between CU TTO and the Boulder Innovation Center, a Boulder business development organization.

About 3QMatrix, Inc.
3QMatrix focuses on the development and commercialization of novel wound healing and drug delivery products using a proprietary product platform. This technology can be used for wound care and slow release drug delivery by both the trans-dermal and subcutaneous routes, offering patients a safer and more effective treatment for a variety of serious diseases. The company plans to introduce a comprehensive line of products based on this proprietary technology platform, to address unmet needs in clinical practice, and to do so in a cost-effective manner. For more information, please go to http://www.3qmatrix.com/.

No comments:

Post a Comment